- Home
- VNOM vs PTGX Comparison
VNOM vs PTGX Comparison
Compare VNOM & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VNOM | PTGX |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 9.3B |
| IPO Year | 2025 | 2016 |
Fundamental Metrics
Financial Performance| Metric | VNOM | PTGX |
|---|---|---|
| Price | $46.94 | $139.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 20 | 14 |
| Target Price | $55.45 | ★ $178.21 |
| AVG Volume (30 Days) | ★ 2.0M | 722.9K |
| Earning Date | 11-02-2026 | 11-05-2026 |
| Dividend Yield | ★ 5.51% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 1.27 | ★ 2.35 |
| Revenue | ★ $1,395,000,000.00 | N/A |
| Revenue This Year | $81.66 | $1,077.07 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $35.67 | $59.42 |
| Revenue Growth | ★ 62.02 | N/A |
| 52 Week Low | $35.10 | $74.03 |
| 52 Week High | $51.13 | $160.81 |
Technical Indicators
Market Signals| Indicator | VNOM | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 69.50 | 48.84 |
| Support Level | $44.30 | $135.10 |
| Resistance Level | $48.73 | $142.20 |
| Average True Range (ATR) | 1.11 | 6.12 |
| MACD | 0.48 | 0.22 |
| Stochastic Oscillator | 94.87 | 49.12 |
Price Performance
Historical ComparisonAbout VNOM Viper Energy Inc.
Viper Energy Inc is focused on owning and acquiring mineral and royalty interests in oil and natural gas properties in the Permian Basin. The Permian Basin is known to have a number of zones of oil and natural gas-bearing rock throughout.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.